Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors

S. Novello; G. V. Scagliotti; R. Rosell; M. A. Socinski; J. Brahmer; J. Atkins; C. Pallares; R. Burgess; L. Tye; P. Selaru; E. Wang; R. Chao; R. Govindan

doi:10.1038/sj.bjc.6605629

Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors

S. Novello, G. V. Scagliotti, R. Rosell, M. A. Socinski, J. Brahmer, J. Atkins, C. Pallares, R. Burgess, L. Tye, P. Selaru, E. Wang, R. Chao, R. Govindan

School of Medicine

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1311
Number of pages	1
Journal	British journal of cancer
Volume	102
Issue number	8
DOIs	https://doi.org/10.1038/sj.bjc.6605629
State	Published - Apr 2010

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/sj.bjc.6605629

Cite this

Novello, S., Scagliotti, G. V., Rosell, R., Socinski, M. A., Brahmer, J., Atkins, J., Pallares, C., Burgess, R., Tye, L., Selaru, P., Wang, E., Chao, R., & Govindan, R. (2010). Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors. British journal of cancer, 102(8), 1311. https://doi.org/10.1038/sj.bjc.6605629

@article{302b0dda56eb431ea3a54af0f1f40f1e,

title = "Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors",

author = "S. Novello and Scagliotti, {G. V.} and R. Rosell and Socinski, {M. A.} and J. Brahmer and J. Atkins and C. Pallares and R. Burgess and L. Tye and P. Selaru and E. Wang and R. Chao and R. Govindan",

year = "2010",

month = apr,

doi = "10.1038/sj.bjc.6605629",

language = "English (US)",

volume = "102",

pages = "1311",

journal = "British journal of cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "8",

}

TY - JOUR

T1 - Reply

T2 - Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors

AU - Novello, S.

AU - Scagliotti, G. V.

AU - Rosell, R.

AU - Socinski, M. A.

AU - Brahmer, J.

AU - Atkins, J.

AU - Pallares, C.

AU - Burgess, R.

AU - Tye, L.

AU - Selaru, P.

AU - Wang, E.

AU - Chao, R.

AU - Govindan, R.

PY - 2010/4

Y1 - 2010/4

UR - http://www.scopus.com/inward/record.url?scp=77950862996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950862996&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6605629

DO - 10.1038/sj.bjc.6605629

M3 - Letter

AN - SCOPUS:77950862996

SN - 0007-0920

VL - 102

SP - 1311

JO - British journal of cancer

JF - British journal of cancer

IS - 8

ER -

Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this